.png)
.png)
.png){kind=spacer}
Overview of Visfatin Levels in Pregnant Women as a Stunting Biomarker
Abstract
Stunting is one of the malnutrition problems experienced by toddlers in the world. Indonesia is the third country in the prevalence of stunting in the Southeast Asian region. Visfatin is one of the molecules that play a role in fetal development during the womb. Reports related to visfatin in pregnant women are still very few, and mention visfatin plays a role in the incidence of preeclampsia (PE), fetal growth restriction, and gestational diabetes mellitus (GDM). This study aims to determine the level of visfatin in pregnant women as a biomarker of stunting in Bangli Regency, Bali Province. This research is a descriptive study, with an observational design. Blood samples were taken from the median cubital vein. Samples were examined by ELISA method. In the examination of vistafin levels in 30 pregnant women, the lowest level being 0.53 ng/ml and the highest level being 56.72 ng/ml. From the results obtained and compared with previous studies, the visfatin levels obtained were lower than the visfatin levels in normal pregnant women. Many studies have shown that increased levels of visfatin in maternal plasma are associated with low birth weight and intrauterine growth restriction (IUGR). Babies born with LBW have a risk of stunting.
Keywords
Full Text:
PDFReferences
Kemenkes RI, “Situasi Balita Pendek (Stunting) di Indonesia,” Kementeri. Kesehat. RI, vol. 301, no. 5, pp. 1163–1178, 2018.
S. M. Kiik and M. S. Nuwa, “Maternal factors in stunting among vulnerable children,” J. Keperawatan Indones., vol. 24, no. 2, pp. 82–89, 2021, doi: 10.7454/jki.v24i2.1306.
Kemenkes RI, “Hasil Riset Kesehatan Dasar Tahun 2018,” Kementrian Kesehat. RI, vol. 53, no. 9, pp. 1689–1699, 2018.
Soetjiningsih and G. Ranuh, Tumbuh Kembang Anak, Edisi 2. Jakarta: EGC, 2013.
A. Candra, Epidemiologi Stunting, 1st ed. Semarang: Fakultas Kedokteran Universitas Diponegoro Semarang, 2020.
A. Fukuhara et al., “Visfatin : A Protein Secreted by Visceral Fat That Mimics the Effects of Insulin Visfatin : A Protein Secreted by Visceral Fat That Mimics the Effects of Insulin,” Science (80-. )., vol. 307, no. 426, 2005, doi: 10.1126/science.1097243.
I. Ihsan, E. A. Rini, and R. Yaswir, “Visfatin levels in non-obese, obese, and insulin resistant adolescents,” Pediatr. Indones., vol. 56, no. 5, pp. 291–296, 2016, doi: 10.14238/pi56.5.2016.291-6.
M. Nourbakhsh, M. Nourbakhsh, Z. Gholinejad, and M. Razzaghy-Azar, “Visfatin in obese children and adolescents and its association,” Scand. J. oof Clin. Lab. Investig., vol. 75, pp. 183–188, 2015, doi: 10.3109/00365513.2014.1003594.
A. F. A. Ferreira, J. C. Rezende, R. D. C. C. Oliveira, R. Akolekar, and K. H. Nicolaides, “Maternal serum visfatin at 11–13 weeks’ gestation in preeclampsia,” J. Hum. Hypertens., vol. 27, pp. 261–264, 2013, doi: 10.1038/jhh.2012.10.
W. Hu, Z. Wang, H. Wang, H. Huang, and M. Dong, “Serum visfatin levels in late pregnancy and pre-eclampsia,” Acta Obstet. Gynecol. Scand., vol. 87, no. 4, pp. 413–418, 2008, doi: 10.1080/00016340801976012.
Ashraf Saber Mashhad Taraqi. et al., "Visfatin as a predictor for growth of fetus and infant", Turk J Obstet Gynecol., vol. 20, no. 5, pp. 80-6, 2018, doi: 10.4274/tjod.48091.
Georgios Valsamakis. et al., "First trimester maternal BMI is a positive predictor of cord blood c-peptide levels while maternal visfatin levels is a negative predictor of birth weight", Hormones., vol.13, no.1 pp.87-94, 2014, doi:10.1007/BF03401324.
S. Mazaki-Tovi et al., “Maternal visfatin concentration in normal pregnancy,” J. Perinat. Med., vol. 37, no. 3, pp. 206–217, 2009, doi: 10.1515/JPM.2009.054.
D G. Haider., Ammon Handisurya., Angela Storka., Elena Vojtassakova., Anton Luger., Giovanni Pacini., Andrea Tura., Michael Wolzt., and Alexandra Kautzky-Willer., "Visfatin Response To Glucose Is Reduced In Women With Gestational Diabetes Mellitus,'' Diabetes Care., vol. 30, no. 7, pp. 1889-91, 2007, doi.org/10.2337/dc07-0013
M. Akturk., A.E. Altinova., I. Mert., U. Buyukkagnici., A. Sargin., M. Arslan., and N. Danisman., "Visfatin concentration is decreased in women with gestational diabetes mellitus in the third trimester," J. Endocrinol. Invest., vol. 31, no. 1 pp: 610-3, 2008, doi. oi: 10.1007/BF03345611.
J. Szamatowicz et al., “Serum visfatin concentration is elevated in pregnant women irrespectively of the presence of gestational diabetes,” Ginekol. Pol., vol. 80, no. 1, pp. 14–18, 2009.
Asmat Shaheen., Zahoor Ahmed., Ihsanullah Khan., Rubina Nazli., and Salim Khattak., "Maternal Serum Visfatin Level In Pre-Eclampsia And Late Pregnancy And Its Effects On Biochemical Parameters," J. Med. Sci., vol. 25, no. 2, pp: 246-51, 2017.
T. F. Chan et al., “Decreased Plasma Visfatin Concentrations in Women With Gestational Diabetes Mellitus,” J. Soc. Gynecol. Investig., vol. 13, no. 5, pp. 364–367, 2006, doi: 10.1016/j.jsgi.2006.04.007.
Y. D. C. Salan, “Biomarker Terkini Dalam Usaha Memprediksi Preeklampsia,” Berk. Kedokt., vol. 13, no. 1, p. 119, 2017, doi: 10.20527/jbk.v13i1.3448.
A. Dakroub et al., “Visfatin : A Possible Role in Cardiovasculo-Metabolic Disorders,” Cells, vol. 9, no. Il, pp. 1–19, 2020.
K. L. Bogan and C. Brenner, “Nicotinic acid, nicotinamide, and nicotinamide riboside: A molecular evaluation of NAD+ precursor vitamins in human nutrition,” Annu. Rev. Nutr., vol. 28, pp. 115–130, 2008, doi: 10.1146/annurev.nutr.28.061807.155443.
S. Mazaki-Tovi et al., “Could alterations in maternal plasma visfatin concentration participate in the phenotypes definition of preeclampsia and SGA?,” J Matern Fetal Neonatal Med, vol. 23, no. 8, pp. 857–868, 2010, doi: 10.3109/14767050903301017.Could.
A. S. M. Taraqi et al., “Visfatin as a predictor for growth of fetus and infant,” Turkish J. Obstet. Gynecol., vol. 15, no. 2, pp. 80–86, 2018, doi: 10.4274/tjod.48091.
A. Malamitsi-Puchner, D. D. Briana, M. Boutsikou, E. Kouskouni, D. Hassiakos, and D. Gourgiotis, “Perinatal circulating visfatin levels in intrauterine growth restriction,” Pediatrics, vol. 119, no. 6, 2007, doi: 10.1542/peds.2006-2589.
Y. Suwarni, M. S. Noor, and A. Rahayu, “Hubungan antara Paritas, LILA, Kadar Hb, dan Usia Ibu Hamil dengan Berat Lahir Bayi,” Kesmas J. Kesehat. Masy. Nas., vol. 8, no. 1, pp. 19–27, 2013.
A. Rahayu, Y. Fahrini, P. A. Octaviana, and R. Fauzie, “Riwayat Berat Badan Lahir dengan Kejadian Stunting pada Anak Usia Bawah Dua Tahun,” J. Kesehat. Masy. Nas., vol. 10, no. 2, pp. 67–73, 2015.
F. C. Murti, S. Suryati, and E. Oktavianto, “Hubungan Berat Badan Lahir Rendah (Bblr)Dengan Kejadian Stunting Pada Balita Usia 2-5 Tahun Di Desa Umbulrejo Kecamatan Ponjong Kabupaten Gunung Kidul,” J. Ilm. Kesehat. Keperawatan, vol. 16, no. 2, pp. 52–60, 2020, doi: 10.26753/jikk.v16i2.419.
T. Beal, A. Tumilowicz, A. Sutrisna, D. Izwardy, and L. M. Neufeld, “A review of child stunting determinants in Indonesia,” Matern. Child Nutr., vol. 14, no. 4, pp. 1–10, 2018, doi: 10.1111/mcn.12617.
M. Fasshauer et al., “Serum levels of the adipokine visfatin are increased in pre-eclampsia,” Clin. Endocrinol. (Oxf)., vol. 69, no. 1, pp. 69–73, 2008, doi: 10.1111/j.1365-2265.2007.03147.x.
S. Mazaki-Tovi et al., “Could alterations in maternal plasma visfatin concentration participate in the phenotype definition of preeclampsia and SGA?,” J Matern Fetal Neonatal Med, vol. 23, no. 8, pp. 857–868, 2013, doi: 10.3109/14767050903301017.Could.
M. Fasshauer, M. Blüher, M. Stumvoll, P. Tönessen, R. Faber, and H. Stepan, “Differential regulation of visfatin and adiponectin in pregnancies with normal and abnormal placental function,” Clin. Endocrinol. (Oxf)., vol. 66, no. 3, pp. 434–439, 2007, doi: 10.1111/j.1365-2265.2007.02751.x.
DOI: https://doi.org/10.31983/jkb.v12i1.8018
Article Metrics
Refbacks
- There are currently no refbacks.
Abstracted/Indexed by:
 |
|
|
|
|
|
Jurnal Kebidanan by http://ejournal.poltekkes-smg.ac.id/ojs/index.php/jurkeb is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
View My Stats aw